Plasma COOH-terminal proendothelin-1: A marker of fatal cardiovascular events, all-cause mortality, and new-onset albuminuria in type 2 diabetes? (ZODIAC-29)

Diabetes Care

Volumn 35, Issue 11, 2012, Pages 2354-2358

  Drion, Iefke ^a   Kleefstra, Nanne ^a,b,c   Landman, Gijs W D ^a   Alkhalaf, Alaa ^a,c   Struck, Joachim ^d   Groenier, Klaas H ^a,c   Bakker, Stephan J L ^c   Bilo, Henk J G ^a,c  

^a ISALA HOSPITAL   (Netherlands)

^b LANGERHANS MEDICAL RESEARCH GROUP   (Netherlands)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^d THERMO FISHER SCIENTIFIC   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

PREPROENDOTHELIN 1;

ADULT; AGED; ALBUMINURIA; ARTICLE; CARDIOVASCULAR MORTALITY; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE MARKER; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RISK FACTOR;

ADULT; ALBUMINURIA; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; ENDOTHELIN-1; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; PROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84868142047     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc11-2526     Document Type: Article

References (27)

1. Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998;339:229-234 (Pubitemid 28350165)
2. Fernández-Real JM, Ricart W. Insulin resistance and chronic cardiovascular inflammatory syndrome. Endocr Rev 2003;24:278-301 (Pubitemid 36724371)
3. Haak T, Jungmann E, Felber A, Hillmann U, Usadel KH. Increased plasma levels of endothelin in diabetic patients with hypertension. Am J Hypertens 1992;5:161-166
4. Perfetto F, Tarquini R, Tapparini L, Tarquini B. Influence of non-insulin-dependent diabetes mellitus on plasma endothelin-1 levels in patients with advanced atherosclerosis. J Diabetes Complications 1998;12:187-192 (Pubitemid 28284747)
5. Inoue A, Yanagisawa M, Kimura S, et al. The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes. Proc Natl Acad Sci USA 1989;86:2863-2867 (Pubitemid 19112640)
6. InoueA, Yanagisawa M, Takuwa Y, Mitsui Y, Kobayashi M, Masaki T. The human preproendothelin-1 gene. Complete nucleotide sequence and regulation of expression. J Biol Chem 1989;264:14954-14959 (Pubitemid 19237323)
7. Agapitov AV, Haynes WG. Role of endothelin in cardiovascular disease. J Renin Angiotensin Aldosterone Syst 2002;3:1-15 (Pubitemid 34475087)
8. Papassotiriou J, Morgenthaler NG, Struck J, Alonso C, Bergmann A. Immunoluminometric assay for measurement of the C-terminal endothelin-1 precursor fragment in human plasma. Clin Chem 2006;52:1144-1151 (Pubitemid 43794428)
9. Struck J, Morgenthaler NG, Bergmann A. Proteolytic processing pattern of the endothelin-1 precursor in vivo. Peptides 2005;26:2482-2486 (Pubitemid 41676720)
10. Takahashi K, Ghatei MA, Lam HC, O'Halloran DJ, Bloom SR. Elevated plasma endothelin in patients with diabetes mellitus. Diabetologia 1990;33:306-310 (Pubitemid 20161886)
11. Mather KJ, Mirzamohammadi B, Lteif A, Steinberg HO, Baron AD. Endothelin contributes to basal vascular tone and endothelial dysfunction in human obesity and type 2 diabetes. Diabetes 2002;51:3517-3523 (Pubitemid 35403459)
12. Güvener N, Aytemir K, Aksöyek S, Gedik O. Plasma endothelin-1 levels in noninsulin dependent diabetes mellitus patients with macrovascular disease. Coron Artery Dis 1997;8:253-258 (Pubitemid 27359171)
13. Schneider JG, Tilly N, Hierl T, et al. Elevated plasma endothelin-1 levels in diabetes mellitus. Am J Hypertens 2002;15:967-972 (Pubitemid 35217402)
14. Maier C, Clodi M, Neuhold S, et al. Endothelial markers may link kidney function to cardiovascular events in type 2 diabetes. Diabetes Care 2009;32:1890-1895
15. Zanatta CM, Gerchman F, Burttet L, et al. Endothelin-1 levels and albuminuria in patients with type 2 diabetes mellitus. Diabetes Res Clin Pract 2008;80:299-304
16. Stehouwer CD, Gall MA, Twisk JW, Knudsen E, Emeis JJ, Parving HH. Increased urinary albumin excretion, endothelial dysfunction, and chronic low-grade inflammation in type 2 diabetes: progressive, interrelated, and independently associatedwith risk of death. Diabetes 2002;51:1157-1165 (Pubitemid 34438363)
17. Ubink-Veltmaat LJ, Bilo HJ, Groenier KH, Houweling ST, Rischen RO,Meyboom-de Jong B. Prevalence, incidence and mortality of type 2 diabetes mellitus revisited: a prospective population-based study in The Netherlands (ZODIAC-1). Eur J Epidemiol 2003;18:793-800 (Pubitemid 37039978)
18. Lutgers HL, Graaff R, Links TP, et al. Skin autofluorescence as a noninvasive marker of vascular damage in patients with type 2 diabetes. Diabetes Care 2006;29:2654-2659 (Pubitemid 44912194)
19. Krüger S, Ewig S, Giersdorf S, Hartmann O, Suttorp N, Welte T; German Competence Network for the Study of Community Acquired Pneumonia (CAPNETZ) Study Group. Cardiovascular and inflammatory biomarkers to predict short- and long-term survival in community acquired pneumonia. Am J Respir Crit Care Med 2010;182:1426-1434
20. Harrell FE Jr, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 1996;15:361-387 (Pubitemid 26072233)
21. May S, Hosmer DW. A simplified method of calculating an overall goodness-of-fit test for the Cox proportional hazards model. Lifetime Data Anal 1998;4:109-120 (Pubitemid 128480552)
22. Pencina MJ, D'Agostino RB, Vasan RS. Statistical methods for assessment of added usefulness of new biomarkers. Clin Chem Lab Med 2010;48:1703-1711
23. Sabatine MS, Morrow DA, de Lemos JA, et al. Evaluation of multiple biomarkers of cardiovascular stress for risk prediction and guiding medical therapy in patients with stable coronary disease. Circulation 2012;125:233-240
24. Jankowska EA, Filippatos GS, von Haehling S, et al. Identification of chronic heart failure patients with a high 12-month mortality risk using biomarkers including plasma C-terminal pro-endothelin-1. PLoS ONE 2011;6:e14506
25. Adlbrecht C, Hülsmann M, Strunk G, et al. Prognostic value of plasma midregional pro-adrenomedullin andC-terminal-pro-endothelin-1 in chronic heart failure outpatients. Eur J Heart Fail 2009;11:361-366
26. Cook NR. Methods for evaluating novel biomarkers - a new paradigm. Int J Clin Pract 2010;64:1723-1727
27. Pencina MJ, D'Agostino RB Sr, D'Agostino RB Jr, Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 2008;27:157-172; discussion 207-212